Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
488 active trials5 approved drugs31 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07083479 | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma(AMPLIFY-EAP) | no longer available | — | — | Elicio TherapeuticsINDUSTRY | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07399015 | Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC | no longer available | — | — | Endevica BioINDUSTRY | 0 | Feb 18, 2026 |
| clinicaltrials |
| NCT03756311 | Expanded Access to NanoPac | no longer available | — | — | NanOlogy, LLCINDUSTRY | 0 | Jan 23, 2026 | clinicaltrials |
| NCT04137822 | Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer | no longer available | — | — | Impatients N.V. trading as myTomorrowsINDUSTRY | 2 | Aug 14, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2026source: clinicaltrials